Peer Case Review by Specialist Oncologists

Peer case review is an evidence-based evaluation of complex oncology cases by 2-3 specialist oncologists who provide independent treatment recommendations based on published clinical evidence, NCCN/ESMO/ASCO guidelines, and their clinical expertise. The process produces a consensus report with PubMed citations and clinical trial options.

Unlike a traditional second opinion from a single physician, our peer review involves multiple specialists providing independent assessments. This reduces individual bias and provides a more comprehensive evaluation based on collective expertise. Additionally, our reviews include PubMed-cited recommendations, clinical trial matching across 8 countries, and multi-perspective treatment landscape analysis.

We require de-identified pathology reports, imaging studies (CT, MRI, PET), treatment history including regimens and response, current performance status (ECOG), molecular/genetic markers when available, and specific clinical questions. Full patient identification is not required for initial review. The more complete the documentation, the more accurate the review.

Standard peer review is completed within 48-72 hours of receiving complete clinical documentation. Urgent cases can be expedited within 24 hours upon request. We prioritize time-sensitive cases (e.g., rapidly progressing disease) and will communicate any delays immediately.

Yes. Peer case review is completely free for licensed oncologists. Our platform is sustained through institutional partnerships with hospitals, not physician fees. There are no hidden charges, no subscription fees, and no obligation to refer patients through our network.

The report includes: independent assessments from each reviewer, areas of consensus and divergent opinions, evidence-based treatment recommendations with supporting PubMed citations, clinical trial eligibility assessment across our 8-country network, risk-benefit analysis, prognostic assessment, and suggested next steps. Optional physician-to-physician consultation call is available.

Reviewers are board-certified oncologists and hematologists from our partner institutions across 8 countries (China, India, South Korea, Singapore, Turkey, Germany, USA, and others). All hold active medical licenses, have subspecialty expertise matching the case, and most have academic appointments with published research. Reviewers are selected based on cancer type, prior treatments, and geographic considerations.

Yes. After receiving the report, you can schedule a physician-to-physician consultation call with one or more reviewers to discuss the findings in detail. This is included at no additional cost. Direct communication helps clarify recommendations and facilitates shared decision-making with your patient.

Divergent opinions are valuable and expected in complex cases. The report clearly identifies areas of consensus and disagreement, providing you with multiple perspectives to inform your clinical decision-making. This is a strength, not a weakness, of the peer review process. We present the reasoning behind each opinion so you can weigh the evidence.

We use HIPAA-aligned security protocols including end-to-end encryption, de-identification of patient data, secure document upload with virus scanning, role-based access controls, and complete audit trails. We do not store protected health information (PHI) longer than necessary for case review. All reviewers sign confidentiality agreements.